216 results found.
                  
BARE BONES® - July 31, 2013
Integra LifeSciences received FDA 510(k) clearance for the Integra® Titan™ Reverse Shoulder. Limited U.S. launch is slated for 3Q13. The system features fully i...
BARE BONES® - July 18, 2013
Integra LifeSciences launched the Integra® Total Foot System 2 to address reconstruction and acute fractures in the forefoot, midfoot and hindfoot. The system offers a variety of plates in multiple si...
Looking Back at INFUSE: 2002 to Today
In mid-June, two independent research groups released a long-awaited review of trial data regarding the use of Medtronic’s INFUSE recombinant human bone morphogenetic protein-2 (rhBMP-2). The following timeline summarizes events that brought us here from the product’s initial cle...
BARE BONES® - June 27, 2013
Medtronic and the Australia Therapeutic Goods Administration initiated a recall of unused lots of the Infuse LT-Cage Bone Graft Kit. The kits contain Integra LifeSciences's (IART) Abso...
BARE BONES® - June 26, 2013
Integra LifeSciences received approval under the CE Mark for the Integra® Smart Cervical Solution, a cage plus bone substitute for the treatment of degenerative diseases that require ...
BARE BONES® - May 2, 2013
Integra LifeSciences reported 1Q13 orthopaedic revenue of US $74.9MM, +5% from 1Q12. (U.S. Extremities $31.3MM, +18%, U.S. Spine & Other $43.5MM, -2.8%) (
1Q13 Revenue: Integra LifeSciences
$74.9MM, +5% U.S. Extremities $31.3MM, +18% U.S. Spine & Other $43.5MM, -3%   Private label ortho products down in low-single-digits Extremities driven by regenerative medicine, foot/ankle; all franchises...
BARE BONES® - April 30, 2013
Integra LifeSciences commenced full market release of the Hollywood™ VI device, primarily used in transforaminal lumbar interbody fusion. Features include a variable insertion option and...
BARE BONES® - March 21, 2013
Integra LifeSciences announced successful implantation of >4,000 Integra® IPP-ON® PIP Fusion Systems for fixation of proximal interphalangeal
BARE BONES® - March 20, 2013
Integra LifeSciences introduced the Enhanced Strength and Stiffness rod (ESS+) for use in the treatment of spinal deformity. Controlled market release will occur in 3Q13. ESS+ is available in straight ...
BARE BONES® - March 20, 2013
Integra LifeSciences received FDA 510(k) clearance for its Proximal Humeral Fracture Plate System for the treatment of complex fractures, a complement to the Titan™ shoulder portfolio. Controlled...
BARE BONES® - February 21, 2013
Integra LifeSciences reported 4Q12 orthopaedic revenue of US $93.2MM, +4% from 4Q11, and 2012 revenue of $369.3MM, +12% from 2011. (2012 U.S. $312.8MM, +15%; ex-U.S. $56.4MM, -1%) (Growth refl...
BARE BONES® - February 20, 2013
Integra LifeSciences (IART) received an FDA Warning Letter related to its manufacturing facility located in Añasco, Puerto Rico citing concerns relative to process validations, CAPA, etc. IART believes that it has already
BARE BONES® - October 24, 2012
Integra LifeSciences commenced full U.S. market release of the Integra® Complete Cervical Intervertebral Body Fusion Device (IBD), a zero-profile, standalone IBD for anterior cervical decompression
BARE BONES® - October 24, 2012
Integra Orthopedics posted 3Q12 revenue of US $94.1MM, +9.9% from 3Q11. (U.S. $82.0MM, +12.5%; ex-U.S. $12.1MM, -4.9%; U.S. Extremities $32.9MM, +32.8%; U.S. Spine & Other $49.1MM, +1....
BARE BONES® - October 9, 2012
Integra LifeSciences received FDA clearance of an expanded indication for use of the Vu aPOD™ Prime Intervertebral Body Fusion Device (IBD) in anterior lumbar interbody fusion. The new s...
Final 2Q12 Results
ORTHOWORLD’s estimates place 2Q12 market growth at 5% over 2Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 2Q12, unless otherwise noted.  Exhibit 1 Ort...
2Q12: A First Look at Earnings
ORTHOWORLD’s estimates place preliminary 2Q12 market growth at 5% over 2Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 2Q12, unless otherwise noted. Exhibit 1 Orthopaedic Sales Increas...
BARE BONES® - July 26, 2012
Integra LifeSciences reported 2Q12 orthopaedic revenue of US $95.6MM, +17% from 2Q11. (U.S. $80.7MM, +22%, ex-U.S. $14.9MM, -2%) (
BARE BONES® - June 21, 2012
Integra LifeSciences entered into a contract to distribute a private label version of the new Stainless Headed Compression Screw System, manufactured by aap Implantate. The system is intended ...
BARE BONES® - June 20, 2012
Integra LifeSciences introduced the IPP-ON® PIP Fusion System for fixation of proximal interphalangeal joint arthrodesis, indicated for lesser toes for rigid or semi-rigid hammertoe deformity...
First Look at Quarterly Results: 1Q12 vs. 1Q11
ORTHOWORLD’s preliminary estimates place overall 1Q12 market growth at 3% over 1Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 1Q12, unless noted otherwise. Exhibit 1 Orthopaedic Sales1 Increase...
BARE BONES® - April 25, 2012
Integra LifeSciences reported 1Q12 orthopaedic revenue of US $86.1MM, +19% from 1Q11. (U.S. $71.2MM, +22%; ex-U.S. $14.9MM, +9%; U.S. Extremities $26.5MM, +25%, U.S. Spine & Other $44....
BARE BONES® - April 17, 2012
Integra LifeSciences commenced full U.S. market release of the Integra® Vu aPOD™ Prime Intervertebral Body Fusion Device (IBD), its 1st zero-profile, standalone IBD designed for
BARE BONES® - March 22, 2012
Integra LifeSciences announced the 1st implantations of the PyroTITAN® Humeral Resurfacing Implant  in Italy and  Sweden. The PyroCarbon-based device is available in 12 sizes
  • ORTHOWORLD INC.
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2019 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group